These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36823470)

  • 21. The optimal duration of triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials.
    Wang W; Huang Q; Pan D; Zheng W; Zheng S
    Int J Cardiol; 2022 Jun; 357():33-38. PubMed ID: 35364137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antithrombotic therapy in atrial fibrillation patients with coronary artery disease: shifting paradigm to a "less is more" concept regimen.
    Kawakami S; Yasuda S; Ogawa H
    J Cardiol; 2020 Jul; 76(1):35-43. PubMed ID: 32389534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct Oral Anticoagulants Would Be Best Choice for Atrial Fibrillation Patients After Coronary Stenting: Retrospective Study in a Japanese Population.
    Koiwaya H; Watanabe N; Kuriyama N; Shibata Y
    Kurume Med J; 2023 Jul; 68(2):97-106. PubMed ID: 37100602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Saito Y; Kobayashi Y
    J Cardiol; 2019 Jan; 73(1):1-6. PubMed ID: 30293674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.
    Angiolillo DJ; Goodman SG; Bhatt DL; Eikelboom JW; Price MJ; Moliterno DJ; Cannon CP; Tanguay JF; Granger CB; Mauri L; Holmes DR; Gibson CM; Faxon DP
    Circulation; 2018 Jul; 138(5):527-536. PubMed ID: 30571525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention.
    Olivier CB; Fan J; Askari M; Mahaffey KW; Heidenreich PA; Perino AC; Leef GC; Ho PM; Harrington RA; Turakhia MP
    Circ Cardiovasc Interv; 2019 Aug; 12(8):e007604. PubMed ID: 31416357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
    Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis.
    Haller PM; Sulzgruber P; Kaufmann C; Geelhoed B; Tamargo J; Wassmann S; Schnabel RB; Westermann D; Huber K; Niessner A; Gremmel T
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):226-236. PubMed ID: 31198930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Kwon S; Jung JH; Choi EK; Lee SW; Park J; Lee SR; Kang J; Han K; Park KW; Oh S; Lip GYH
    Korean Circ J; 2021 May; 51(5):409-422. PubMed ID: 33764010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
    Gargiulo G; Goette A; Tijssen J; Eckardt L; Lewalter T; Vranckx P; Valgimigli M
    Eur Heart J; 2019 Dec; 40(46):3757-3767. PubMed ID: 31651946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antithrombotic treatment in atrial fibrillation patients undergoing PCI: Is dual therapy the winner?
    Mantis C; Alexopoulos D
    Thromb Res; 2019 Apr; 176():133-139. PubMed ID: 30826397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiplatelet Therapy in Patients Requiring Oral Anticoagulation and Undergoing Percutaneous Coronary Intervention.
    Manzi L; Florimonte D; Forzano I; Buongiorno F; Sperandeo L; Castiello DS; Paolillo R; Giugliano G; Giacoppo D; Sciahbasi A; Cirillo P; Esposito G; Gargiulo G
    Interv Cardiol Clin; 2024 Oct; 13(4):527-541. PubMed ID: 39245552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting.
    Lacoste JL; Hansen CL
    Am J Health Syst Pharm; 2019 Sep; 76(18):1395-1402. PubMed ID: 31505555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention.
    Koskinas KC; Räber L; Zanchin T; Pilgrim T; Stortecky S; Hunziker L; Blöchlinger S; Billinger M; Gartwyl F; Moro C; Moschovitis A; Jüni P; Heg D; Windecker S
    JACC Cardiovasc Interv; 2016 Jul; 9(14):1473-83. PubMed ID: 27478115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Anticoagulation status and adherence in patients with atrial fibrillation hospitalized for ACS and the impact on 1-year prognosis: a multicenter cohort study].
    Zhu LY; Li Q; Yu LY; Liu Y; Chen YN; Wang Z; Zhang SY; Li J; Liu Y; Zhao YL; Xi Y; Pi L; Sun YH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2023 Jul; 51(7):731-741. PubMed ID: 37460427
    [No Abstract]   [Full Text] [Related]  

  • 37. Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
    Mishra A; Singh M; Acker WW; Kamboj S; Sporn D; Stapleton D; Kaluski E
    J Cardiovasc Pharmacol; 2019 Aug; 74(2):82-90. PubMed ID: 31306367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does HAS-BLED risk score underestimate the risk of bleeding in patients with triple antithrombotic therapy?
    Stojanovic M; Deljanin-Ilic M; Ilic S; Ilic B; Petrovic D
    Pol Merkur Lekarski; 2020 Oct; 48(287):361-364. PubMed ID: 33130800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type.
    Eyileten C; Postula M; Jakubik D; Toma A; Mirowska-Guzel D; Patti G; Renda G; Siller-Matula JM
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32295160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy.
    Berteotti M; Gori AM; Giusti B; Fortini A; Grossi G; Ciardetti N; Migliorini A; Lotti E; Valenti R; Di Mario C; Marchionni N; Marcucci R
    J Thromb Thrombolysis; 2023 May; 55(4):667-679. PubMed ID: 36905562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.